



HOUSE BILL 567: Ensure Access to Biomarker Testing.

2025-2026 General Assembly

Committee:	House Rules, Calendar, and Operations of the House	Date:	May 6, 2025
Introduced by:	Reps. Wheatley, Penny, Campbell, Moss	Prepared by:	Jessica Boney
Analysis of:	Second Edition		Staff Attorney

OVERVIEW: *House Bill 567 would require a health benefit plan, the State Health Plan, and Medicaid to provide coverage for biomarker testing.*

BILL ANALYSIS:

Section 1.1(a) would enact G.S. 58-3-216 (Coverage of biomarker testing) and create definitions, including *biomarker*, *biomarker testing*, *consensus statement*, *independent multidisciplinary panel*, *independent organization or medical professional society*, and *nationally recognized clinical practice guidelines*.

A health benefit plan would be required to provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate care management, or ongoing monitoring of an insured's disease or condition when the testing is supported by medical and scientific evidence.

Section 1.1(b) would amend G.S. 58-3-215 governing genetic information in health insurance to include a definition of biomarker and make conforming changes.

This section would be effective October 1, 2025, and apply to insurance contracts issued, renewed, or amended on or after that date.

Section 1.2 would require the State Health Plan to provide coverage of biomarker testing.

This section would be effective October 1, 2025, and apply as of the start of the next plan year following the effective date.

Section 2.1 would direct the Division of Health Benefits to ensure Medicaid coverage for biomarker testing.

EFFECTIVE DATE: Except as otherwise provided, this act would be effective when it becomes law.

Kara McCraw
Director



Legislative Analysis
Division
919-733-2578